Altimmune to Present at Stifel Cardiometabolic Forum Amid MASH Focus
Event summary
- Altimmune to participate in Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026, at 10:30 a.m. ET.
- Management to engage in a fireside chat, webcast available via Altimmune's website.
- Pemvidutide remains lead candidate targeting MASH, AUD, and ALD.
- Company focuses on dual-action therapy balancing glucagon and GLP-1 receptors.
The big picture
Altimmune's participation in the Stifel Cardiometabolic Forum underscores its strategic pivot toward metabolic liver diseases, particularly MASH. The company's focus on pemvidutide aligns with broader industry trends favoring multi-target therapies for complex conditions. With the cardiometabolic market expanding, Altimmune's ability to secure investor interest will hinge on demonstrating clear clinical and commercial differentiation.
What we're watching
- Clinical Progress
- How pemvidutide's dual-action mechanism will impact MASH trial outcomes.
- Market Positioning
- Whether Altimmune can differentiate itself in the competitive cardiometabolic space.
- Investor Sentiment
- The pace at which investor confidence grows following forum insights.